BioNTech’s Founders Spin Off mRNA as $1 Billion Buyback Backs a Cancer-First Future
Veröffentlicht: 06.05.2026 um 23:00 Uhr, Redaktion boerse-global.de
The German biotech powerhouse is rewriting its playbook. BioNTech’s first-quarter 2026 results tell a story of two companies in one: a shrinking COVID-vaccine cash cow and an ambitious oncology pivot that has yet to prove its commercial worth. Yet management is doubling down, authorizing a $1 billion share buyback and spinning off its mRNA roots into a separate entity led by the founders themselves.
Losses Widen, but the Balance Sheet Remains a Fortress
Revenue for the three months ended March 31 tumbled 35% year-on-year to €118 million, dragged lower by the relentless decline in COVID-19 vaccine sales. The net loss deepened to €532 million from €416 million in the prior-year period, with research spending swelling to €557 million as the company integrates recent acquisitions in China and assets from CureVac.
Despite the red ink, BioNTech’s adjusted loss per American Depositary Share came in at $1.95 — a full $0.32 better than analysts had penciled in. The company’s financial firepower remains formidable: cash, cash equivalents and securities stood at €16.8 billion at quarter-end, providing ample room for the buyback and the costly oncology pivot.
Founders Take the mRNA Reins in a Strategic Divorce
In a move that marks a clear break from the past, Professors Ugur Sahin and Ă–zlem TĂĽreci will lead a newly formed, independent company focused exclusively on advancing mRNA technology. BioNTech plans to transfer specific technologies and licensing rights to the spin-off, with formal terms expected later this year.
Should investors sell immediately? Or is it worth buying BioNTech?
The core entity, meanwhile, is shedding its platform-centric identity to become a “multiproduct oncology company” by 2030 — targeting common cancers such as lung and breast cancer. The restructuring underscores a fundamental shift: BioNTech is no longer a one-trick vaccine pony, but a biotech betting its future on tumor-specific therapies.
Buyback Signals Undervaluation as COVID Pipeline Stalls
The board and supervisory board have approved a $1 billion share repurchase program for American Depositary Shares over the next 12 months. Management justified the move by stating it wants to deploy capital “when the share price is disconnected from intrinsic value.”
The timing is telling. BioNTech and partner Pfizer halted enrollment in a large US study for their updated COVID vaccine after more than 80% of candidates failed screening criteria due to conditions like hypertension and diabetes — safety was not a factor. The company expects COVID revenue to fall again in 2026, with the bulk of annual sales concentrated in the final four months.
The stock has felt the pressure. Trading around €81, it sits nearly 20% below its 52-week high and lost almost 7% in the past seven days — even on days when the Nasdaq gained ground. The buyback could act as a floor, provided the necessary authorizations are granted.
Oncology Pipeline Takes Center Stage at ASCO
All eyes are now on Pumitamig (BNT327), the cornerstone of BioNTech’s cancer strategy. The company launched five new registration trials for the drug in the first quarter alone, targeting triple-negative breast cancer, gastric cancer and colorectal cancer.
Six late-stage clinical data packages are expected this year, starting with results from the ROSETTA Lung-02 study at the ASCO conference in late May. Updates on the antibody-drug conjugate portfolio, including Trastuzumab Pamirtecan, will also be presented. These data points will be the market’s first real test of whether the oncology pivot has legs.
BioNTech at a turning point? This analysis reveals what investors need to know now.
Factory Closures and a Dividend-Free Future
BioNTech plans to shutter its sites in Idar-Oberstein, Marburg and Tübingen by the end of 2027, along with its Singapore facility. The company is exploring sale options for all locations, with annual cost savings expected to reach €500 million by 2029.
Shareholders won’t see a dividend anytime soon. The annual general meeting on May 15 is expected to retain the entire retained profit of roughly €6.9 billion, reinforcing the message that every euro is being funneled into the cancer transformation.
For the full year, BioNTech maintains its revenue guidance of €2.0 billion to €2.3 billion — a target that hinges on convincing the market that its oncology pipeline can fill the void left by fading COVID sales. Whether the ASCO data delivers that conviction remains the open question.
Ad
BioNTech Stock: New Analysis - 6 May
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
